Safety and Immunogenicity of a Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Vaccine in HIV-Infected Children 7 to 12 Years Old

Abstract

Background-Quadrivalent human papillomavirus vaccine (QHPV) is >95% effective in preventing infection with vaccine-type human papillomavirus. The safety and immunogenicity of QHPV are unknown in HIV-infected children.

Cervical Cancer Screening and Prevention for HIV-Infected Women in the Developing World

“…As yet there are limited data on safety, immune response and efficacy of the HPV vaccine in HIV+ women, although studies are on-going. Although data on the safety of the quadrivalent vaccine in HIV-infected children has been demonstrated, efficacy of the currently available HPV vaccines in women or girls with HIV has not yet been established (Levin et al 2010).…”

Vaccinal Prevention of the Diseases Caused by Human Papillomavirus: Evidence-Based Medicine. Review of Clinical Guidelines

“…В настоящее время накоплены результаты клини-ческих исследований у пациентов разных возрастов и полов, страдающих ВИЧ-инфекцией, которые проде-монстрировали высокий уровень безопасности и имму-ногенности квадривалентной вакцины [61][62][63][64].…”

Clinical Manifestations of HIV-Infection in the Era of Highly Active Antiretroviral Therapy

“…-Human papillomavirus (HPV) vaccine. Data of quadrivalent human papillomavirus vaccine (QHPV) in HIV-infected children (60% female) aged from 7 to 12 years, with a CD4% ≥15 and on stable antiretroviral therapy showed that the vaccine is safe and immunogenic for the 4 antigens (Levin, 2010). Although the data are limited, this vaccine is recommended for girls from 12 years of age (minimum age 9, maximum age 26 years), irrespective of CD4 count in a 3 dose schedule.…”